Nasal dissemination of a single-clone IgH-rearranged conjunctival MALT lymphoma through the nasolacrimal duct: A case report

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

The aim of the present study was to report a rare case of single-clone, immunoglobulin heavy chain (IgH)-rearranged mucosa-associated lymphoid tissue (MALT) lymphoma in the conjunctiva, with nasal cavity dissemination through the nasolacrimal duct. A 24-year-old female was diagnosed with MALT lymphoma of the nasal cavity at the Department of Otolaryngology, Wan Fang Medical Center, Taipei Medical University (Tapei, Taiwan) in October 2008. A biopsy of the relapsing conjunctival lesion revealed a MALT lymphoma by pathological staining, while a single-clone, IgH-rearranged tumor lesion in the nasal cavity and conjunctiva was confirmed using continuous sinus computed tomography scans and polymerase chain reaction. Tumor lesions were negative for Helicobacter pylori and Chlamydia infection, but exhibited bilateral neck lymph node dissemination. A combination of radiation therapy (a total dosage of 46.8 Gray, in two phases covering the left lacrimal sac, nasal cavity and bilateral neck region) and topical ciprofloxacin plus steroid (0.3% ciprofloxacin 4 times a day and betamethasone eye ointment before sleep for 1 month) was provided as an effective therapeutic strategy, and no recurrence was found in the next 3 years. The nasolacrimal duct serves as a channel for conjunctival tumor spreading and is easily neglected. IgH-involved translocation in MALT lymphoma is a factor in the progression of the disease, and aggressive combination therapy is essential for a high-risk, disseminated IgH-rearranged MALT lymphoma.
原文英語
頁(從 - 到)1007-1010
頁數4
期刊Oncology Letters
12
發行號2
DOIs
出版狀態已發佈 - 八月 1 2016

指紋

Nasolacrimal Duct
Marginal Zone B-Cell Lymphoma
Immunoglobulin Heavy Chains
Nose
Nasal Cavity
Clone Cells
Conjunctiva
Ciprofloxacin
Neck
Betamethasone
Neoplasms
Chlamydia Infections
Otolaryngology
Helicobacter Infections
Ointments
Taiwan
Helicobacter pylori
Disease Progression
Sleep
Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

@article{e830bb86c8c44a5ab8a9c01feed8dbb4,
title = "Nasal dissemination of a single-clone IgH-rearranged conjunctival MALT lymphoma through the nasolacrimal duct: A case report",
abstract = "The aim of the present study was to report a rare case of single-clone, immunoglobulin heavy chain (IgH)-rearranged mucosa-associated lymphoid tissue (MALT) lymphoma in the conjunctiva, with nasal cavity dissemination through the nasolacrimal duct. A 24-year-old female was diagnosed with MALT lymphoma of the nasal cavity at the Department of Otolaryngology, Wan Fang Medical Center, Taipei Medical University (Tapei, Taiwan) in October 2008. A biopsy of the relapsing conjunctival lesion revealed a MALT lymphoma by pathological staining, while a single-clone, IgH-rearranged tumor lesion in the nasal cavity and conjunctiva was confirmed using continuous sinus computed tomography scans and polymerase chain reaction. Tumor lesions were negative for Helicobacter pylori and Chlamydia infection, but exhibited bilateral neck lymph node dissemination. A combination of radiation therapy (a total dosage of 46.8 Gray, in two phases covering the left lacrimal sac, nasal cavity and bilateral neck region) and topical ciprofloxacin plus steroid (0.3{\%} ciprofloxacin 4 times a day and betamethasone eye ointment before sleep for 1 month) was provided as an effective therapeutic strategy, and no recurrence was found in the next 3 years. The nasolacrimal duct serves as a channel for conjunctival tumor spreading and is easily neglected. IgH-involved translocation in MALT lymphoma is a factor in the progression of the disease, and aggressive combination therapy is essential for a high-risk, disseminated IgH-rearranged MALT lymphoma.",
keywords = "Conjunctiva, Immunoglobulin heavy chain translocation, Mucosa-associated lymphoid tissue lymphoma, Nasal cavity, Nasolacrimal duct",
author = "Hsieh, {Chung Yu} and Liao, {Yi Ping} and Wu, {Chia Che} and Yuan, {Sheng Po} and Ho, {Jennifer Hui Chun} and Rachel Roan and Liew, {Phui Ly} and Ming-Tang Lai and Feipeng Lee",
year = "2016",
month = "8",
day = "1",
doi = "10.3892/ol.2016.4700",
language = "English",
volume = "12",
pages = "1007--1010",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Nasal dissemination of a single-clone IgH-rearranged conjunctival MALT lymphoma through the nasolacrimal duct

T2 - A case report

AU - Hsieh, Chung Yu

AU - Liao, Yi Ping

AU - Wu, Chia Che

AU - Yuan, Sheng Po

AU - Ho, Jennifer Hui Chun

AU - Roan, Rachel

AU - Liew, Phui Ly

AU - Lai, Ming-Tang

AU - Lee, Feipeng

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The aim of the present study was to report a rare case of single-clone, immunoglobulin heavy chain (IgH)-rearranged mucosa-associated lymphoid tissue (MALT) lymphoma in the conjunctiva, with nasal cavity dissemination through the nasolacrimal duct. A 24-year-old female was diagnosed with MALT lymphoma of the nasal cavity at the Department of Otolaryngology, Wan Fang Medical Center, Taipei Medical University (Tapei, Taiwan) in October 2008. A biopsy of the relapsing conjunctival lesion revealed a MALT lymphoma by pathological staining, while a single-clone, IgH-rearranged tumor lesion in the nasal cavity and conjunctiva was confirmed using continuous sinus computed tomography scans and polymerase chain reaction. Tumor lesions were negative for Helicobacter pylori and Chlamydia infection, but exhibited bilateral neck lymph node dissemination. A combination of radiation therapy (a total dosage of 46.8 Gray, in two phases covering the left lacrimal sac, nasal cavity and bilateral neck region) and topical ciprofloxacin plus steroid (0.3% ciprofloxacin 4 times a day and betamethasone eye ointment before sleep for 1 month) was provided as an effective therapeutic strategy, and no recurrence was found in the next 3 years. The nasolacrimal duct serves as a channel for conjunctival tumor spreading and is easily neglected. IgH-involved translocation in MALT lymphoma is a factor in the progression of the disease, and aggressive combination therapy is essential for a high-risk, disseminated IgH-rearranged MALT lymphoma.

AB - The aim of the present study was to report a rare case of single-clone, immunoglobulin heavy chain (IgH)-rearranged mucosa-associated lymphoid tissue (MALT) lymphoma in the conjunctiva, with nasal cavity dissemination through the nasolacrimal duct. A 24-year-old female was diagnosed with MALT lymphoma of the nasal cavity at the Department of Otolaryngology, Wan Fang Medical Center, Taipei Medical University (Tapei, Taiwan) in October 2008. A biopsy of the relapsing conjunctival lesion revealed a MALT lymphoma by pathological staining, while a single-clone, IgH-rearranged tumor lesion in the nasal cavity and conjunctiva was confirmed using continuous sinus computed tomography scans and polymerase chain reaction. Tumor lesions were negative for Helicobacter pylori and Chlamydia infection, but exhibited bilateral neck lymph node dissemination. A combination of radiation therapy (a total dosage of 46.8 Gray, in two phases covering the left lacrimal sac, nasal cavity and bilateral neck region) and topical ciprofloxacin plus steroid (0.3% ciprofloxacin 4 times a day and betamethasone eye ointment before sleep for 1 month) was provided as an effective therapeutic strategy, and no recurrence was found in the next 3 years. The nasolacrimal duct serves as a channel for conjunctival tumor spreading and is easily neglected. IgH-involved translocation in MALT lymphoma is a factor in the progression of the disease, and aggressive combination therapy is essential for a high-risk, disseminated IgH-rearranged MALT lymphoma.

KW - Conjunctiva

KW - Immunoglobulin heavy chain translocation

KW - Mucosa-associated lymphoid tissue lymphoma

KW - Nasal cavity

KW - Nasolacrimal duct

UR - http://www.scopus.com/inward/record.url?scp=84977098270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977098270&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.4700

DO - 10.3892/ol.2016.4700

M3 - Article

AN - SCOPUS:84977098270

VL - 12

SP - 1007

EP - 1010

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -